We report a case of bilateral acute depigmentation of the iris in which satisfactory intraocular pressure control was obtained after resolution of the acute disease with a trabecular implant (iStent ® ). A 62-year-old woman presented with bilateral simultaneous acute eye pain, photophobia, increased intraocular pressure (34 mmHg), circulating pigment in the anterior chamber, areas of depigmentation in the iris, and posterior synechiae. She had received oral amoxicillin-clavulanate and moxifloxacin for pneumonia 2 months previously. Bilateral acute depigmentation of the iris was suspected as well as a viral etiology. She received oral acetazolamide, aciclovir, and prednisone, besides topical prednisolone, betaxolol, brimonidine, dorzolamide, and atropine. The disease gradually resolved in 4 months but, after 1 year, she developed bilateral cataracts, and still needed three drugs for intraocular pressure control (16/18 mmHg). Cataract-iStent ® combined surgery was performed in both eyes. One year after surgery, intraocular pressure was 11/12 mmHg, without medication. iStent ® was safe and effective on this secondary glaucoma.
A malattia leventinese ou distrofia macular de Doyne é uma doença autossômica dominante rara, causada por uma mutação no gene EFEMP1, caracterizada pela presença de inúmeras drusas com distribuição radial no polo posterior. Trata-se de uma paciente de 39 anos de idade que apresentou, à consulta oftalmológica, queixa de baixa acuidade visual no olho esquerdo (OE) percebida há aproximadamente dois anos. Foi aventada a hipótese diagnóstica de malattia leventinese com neovascularização de coroide no olho esquerdo, após avaliação clínica e propedêutica complementar.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.